Schrodinger Inc (SDGR) Options

This needs to turn around soon. So oversold.

Beast mode

Love this ticker

Up 20%. Guess was right… adding.

Now is the time to add.

Cathy Woods adding

This was a fun move hope someone followed ;) 8% at peak today ftw

Nice set up if gets into 60

M and A -------------------------
merger looming---microsoft

Smh

Any insight to this upward move after hours?

Very Solid company with HUGE money supporting it...Long term Hold this is a golden ticket going forward $100 PT this time next year!

Little action AH

Still running

I am not holding shares. It may run some more, plus not everyone is familiar with Citron the beast! > LOL.

yea he exaggerates his long ideas. TLRY,RVLV come to mind

Citron > will they be shorting tomorrow? Playing off the TSLA hype!

Bullish

https://citronresearch.com/schrodinger-sdgr-taking-drug-discovery-to-the-space-age/

Citron pump

https://twitter.com/CitronResearch/status/1230538195726503942

Citron Research
@CitronResearch
$SDGR the most important IPO past 5 years. Taking drug discovery to "space age". The parallels to an early stage $TSLA are too obvious to ignore. Don't take Citron's word, look at the majority shareholders AI molecular simulation is real disruption. TGT- $80

Still running

Schrodinger Shares Surge 55% After IPO Priced Above High End of Range >SDGR
12:39 pm ET February 6, 2020 (Dow Jones) Print
By Colin Kellaher

Shares of Schrodinger Inc. (SDGR) jumped more than 55% in their trading debut Thursday after the drug discovery software company's upsized initial public offering of 11.9 million shares was priced at $17 apiece, above the expected range.

Schrodinger shares recently were trading at $26.54, up about 56%, after opening at $26.

The New York company, whose investors include D.E. Shaw and the Bill & Melinda Gates Foundation, previously said it planned to sell 10 million shares at $14 to $16 each in the IPO.

The company has granted the underwriters an option to buy up to 1.78 million additional shares.

Schrodinger Inc is headquartered in New York City, New York, United States and is a software publisher. The company's key areas of interest are Computational Chemistry Software, Molecular Modeling, Dockings, Homology Modeling, Cheminformatics, Pharmacophore Modeling, Qsars, Computational Biology, Computer Chemistry, Quantum Chemistry, Software For Chemistry. The company was founded in 1995.